Litcius/Paper detail

Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ

Shereen E. Elkholy, Samah M. Elaidy, Nagla A. El-Sherbeeny, Eman A. Toraih, Hoda W. El-Gawly

2020Life Sciences24 citationsDOI

Topics & Concepts

PioglitazoneNeuroprotectionMedicineEndocrinologyInternal medicineSciatic nerveStreptozotocinPeripheral neuropathyHyperalgesiaDiabetic neuropathyDiabetes mellitusIntraperitoneal injectionType 2 diabetesReceptorNociceptionPain Mechanisms and TreatmentsNerve injury and regenerationPeroxisome Proliferator-Activated Receptors
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ | Litcius